Usana Health Sciences Inc is a company that specializes in the development and manufacturing of nutritional supplements, personal care products, and energy sports products
Focused on promoting health and well-being, Usana combines science with quality in its offerings, delivering products that support a balanced lifestyle. The company markets its products through a direct selling model, engaging a network of independent distributors to reach consumers globally. Usana is committed to research and innovation, ensuring its formulations meet high standards of efficacy and safety while catering to a diverse range of health and wellness needs.
Consumer staples stocks are solid insurance policies in frothy markets ripe for corrections. Unfortunately, the sector hasn’t provided much protection lately as it pulled back by 10% over the past six months. This drop was worse than the S&P 500’s 1.6% fall.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at personal care stocks, starting with USANA (NYSE:USNA).
Let’s dig into the relative performance of The Honest Company (NASDAQ:HNST) and its peers as we unravel the now-completed Q4 personal care earnings season.
What a brutal six months it’s been for USANA. The stock has dropped 31.7% and now trades at a new 52-week low of $27.43, rattling many shareholders. This may have investors wondering how to approach the situation.
Health and wellness products company USANA Health Sciences (NYSE:USNA) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 3.4% year on year to $213.6 million. The company’s full-year revenue guidance of $960 million at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP profit of $0.64 per share was 30.6% above analysts’ consensus estimates.
Health and wellness products company USANA Health Sciences (NYSE:USNA)
will be announcing earnings results tomorrow afternoon. Here’s what investors should know.
Over the past six months, USANA’s shares (currently trading at $37.74) have posted a disappointing 18.2% loss, well below the S&P 500’s 12.1% gain. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the personal care industry, including USANA (NYSE:USNA) and its peers.
Health and wellness products company USANA Health Sciences (NYSE:USNA) fell short of the market’s revenue expectations in Q3 CY2024, with sales falling 6.2% year on year to $200.2 million. The company’s full-year revenue guidance of $850 million at the midpoint also came in 1.4% below analysts’ estimates. Its GAAP profit of $0.56 per share was 15.5% above analysts’ consensus estimates.
USNA stock results show that Usana Health Sciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Study shows no link between daily multivitamin use and lower risk of death in healthy adults. No difference in mortality from cancer, heart disease, or cerebrovascular diseases.
